Evidence map›Paper›PMID 38958918›Full record

ArticleDrugs in R&D2024

Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim.

Henriette Kuehne, Janice M Davis, LeeAnne Merewether, Matthew McQueen, Elizabeth Valentine, Glen Young, Benjamin T Andrews, Dimitri Diaz, Karen J Miller

Abstract read
In one paragraph

Article in Drugs in R&D, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Henriette KuehneCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.ORCID http://orcid.org/0000-0002-9802-9033
Janice M DavisCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
LeeAnne MerewetherCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Matthew McQueenCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Elizabeth ValentineCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Glen YoungCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.ORCID http://orcid.org/0009-0005-4105-8721
Benjamin T AndrewsCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Dimitri DiazCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA.
Karen J MillerCoherus BioSciences Inc., 1000 Avenida Acaso, Camarillo, CA, 93012, USA. kmiller@coherus.com.ORCID http://orcid.org/0009-0001-8125-7187

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPegfilgrastim-cbqv/CHS-1701 (UDENYCA

objectiveThe current study demonstrates the analytical similarity of pegfilgrastim-cbqv and the reference product, pegfilgrastim. In addition to the physicochemical and functional characterization of the protein, the study assessed attributes specific to PEGylation including PEG size and polydispersity, site of attachment, linker composition, and PEGylation process-related variants.

methodsThe structural, functional, and stability attributes of pegfilgrastim-cbqv and pegfilgrastim were compared using state-of-the-art analytical methods. For the protein, the primary structure, disulfide structure, and secondary and tertiary structures were assessed using traditional protein characterization techniques such as mass spectrometry (MS), circular dichroism (CD), intrinsic fluorescence, and differential scanning calorimetry (DSC), as well as more advanced techniques such as two-dimensional (2D) nuclear magnetic resonance (NMR) and hydrogen deuterium exchange (HDX). For the PEG moiety, the site of attachment, occupancy, linker composition, size and polydispersity were compared using mass spectrometry (both intact and after endoprotease digestion), multiangle light scattering detection (MALS), and Edman degradation. Purity assessments included the assessment of both protein variants and PEGylation variants using chromatographic and electrophoretic analytical separation techniques. The functional similarity between pegfilgrastim-cbqv and pegfilgrastim was compared using both a cell-based bioassay and surface plasmon resonance (SPR). The degradation rates and stability profiles were compared under accelerated and stressed conditions.

resultsBiosimilarity was demonstrated by a thorough assessment of physiochemical and functional attributes, as well as comparative stability, of pegfilgrastim-cbqv relative to pegfilgrastim. These studies demonstrated identical primary structure and disulfide structure, highly similar secondary and tertiary structure, as well as functional similarity. The impurity profile of pegfilgrastim-cbqv was comparable to that of pegfilgrastim with only minor differences in PEGylation variants and a slight offset in the PEG molar mass. These differences were not clinically relevant. The degradation profiles were qualitatively and quantitatively similar under accelerated and stress conditions.

conclusionThe structural, functional, and stability data demonstrate that pegfilgrastim-cbqv is highly similar to the reference product, pegfilgrastim.

Indexed as

Biosimilar PharmaceuticalsFilgrastimPolyethylene GlycolsAntineoplastic AgentsChemical PhenomenaFebrile NeutropeniaHematologic AgentsMagnetic Resonance SpectroscopyUnited States Food and Drug AdministrationAntineoplastic AgentsBiosimilar PharmaceuticalsFilgrastimHematologic AgentspegfilgrastimPolyethylene Glycols

Identifiers

PMID38958918
PMCPMC11315836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.